

Original Article

Utility of CEA and CA 15-3 Measurements in Non-Purulent Pleural Exudates in the Diagnosis of Malignancy: A Single-Center Experience[☆]



José M. Porcel,^{a,*} Carme Civit,^a Aureli Esquerda,^b Antonieta Salud,^c Silvia Bielsa^a

^a Unidad de Medicina Pleural, Hospital Universitario Arnau de Vilanova, Instituto de Investigación Biomédica de Lleida Fundación Dr. Pifarré, IRBLLEIDA, Lérida, Spain

^b Servicio de Análisis Clínicos, Hospital Universitario Arnau de Vilanova, Lérida, Spain

^c Servicio de Oncología Médica, Hospital Universitario Arnau de Vilanova, Lérida, Spain

ARTICLE INFO

Article history:

Received 19 November 2016

Accepted 20 December 2016

Available online 23 June 2017

Keywords:

Malignant pleural effusion

CEA

CA 15-3

Tumor markers

Pleural fluid

ABSTRACT

Objective: To establish the diagnostic accuracy of pleural fluid (PF) CEA and CA 15-3 in identifying malignancy, and to determine the additional value of these markers in patients with malignant pleural effusions (MPEs) with false negative results from cytological fluid examination.

Methods: PF concentrations of CEA and/or CA 15-3 were determined in 1575 patients with non-purulent exudates, 549 of whom had confirmed MPEs, 284 probable MPEs, and 742 benign effusions. Tumor marker cut-off points were set to ensure 100% specificity for malignant effusion.

Results: The 41%, 40% and 60% of MPE patients had high PF levels of CEA (>45 ng/mL), CA 15-3 (>77 UI/l) or both, respectively. These percentages were 30%, 19% and 41% in MPEs with positive pleural biopsy and negative PF cytology; and 24%, 13% and 35% in clinical MPEs without histocytological confirmation. Tumor markers were of no value in lymphomas and mesotheliomas. The area-under-the-curve for CEA was 0.819 (95% CI: 0.793–0.845) and for CA 15-3, it was 0.822 (95% CI: 0.796–0.847). The use of tumor markers compared to cytology alone, increased the diagnosis of malignancy by 14%.

Conclusions: Measurements of PF CEA and CA 15-3 may complement pleural cytology in the identification of MPEs.

© 2017 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

Utilidad de la medición de CEA y CA 15-3 en los exudados pleurales no purulentos para diagnosticar malignidad: experiencia de un único centro

RESUMEN

Objetivo: Establecer la rentabilidad diagnóstica de la medición de CEA y CA 15-3 en el líquido pleural (LP) para identificar malignidad, así como el valor adicional de estos marcadores en pacientes con derrame pleural maligno (DPM) y citología pleural falsamente negativa.

Método: Se determinaron las concentraciones de CEA o CA 15-3 en el LP de 1.575 pacientes con exudados no purulentos, de los que 549 tenían DPM demostrados, 284 derrames probablemente malignos y 742 derrames benignos. Se buscaron puntos de corte 100% específicos para dichos marcadores, de forma que no pudieran ser superados por ningún derrame benigno.

Palabras clave:

Derrame pleural maligno

CEA

CA 15-3

Marcadores tumorales

Líquido pleural

[☆] Please cite this article as: Porcel JM, Civit C, Esquerda A, Salud A, Bielsa S. Utilidad de la medición de CEA y CA 15-3 en los exudados pleurales no purulentos para diagnosticar malignidad: experiencia de un único centro. Arch Bronconeumol. 2017;53:427–431.

* Corresponding author.

E-mail address: jporcel@yahoo.es (J.M. Porcel).

Resultados: El 41%, 40% y el 60% de los pacientes con DPM tenían concentraciones pleurales elevadas de CEA (>45 ng/mL), CA 15-3 (>77 UI/l), o de alguno de los anteriores, respectivamente. Estos porcentajes fueron del 30%, 19% y 41% en los DPM con biopsia pleural positiva y estudios citológicos del LP negativos; y del 24%, 13% y 35% en los derrames considerados clínicamente malignos, pero sin demostración citohistológica. Los marcadores tumorales no tuvieron utilidad en linfomas ni mesoteliomas. El área bajo la curva de eficacia diagnóstica (AUC) del CEA fue de 0,819 (IC 95%: 0,793–0,845) y la del CA 15-3 de 0,822 (IC 95%: 0,796–0,847). Globalmente, el uso adicional de los marcadores tumorales incrementó el diagnóstico de malignidad un 14% respecto a la citología pleural de forma aislada.

Conclusiones: La determinación de CEA y CA 15-3 en LP puede complementar a la citología pleural en la identificación de los DPM.

© 2017 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

The easiest way of diagnosing malignant pleural effusion (MPE) is to demonstrate the presence of tumor cells in the cytological examination of pleural fluid (PF).¹ Unfortunately, pleural cytology has a maximum yield of around 60%, and figures are much lower in some tumor types, such as squamous cell lung cancer or mesothelioma (25%–30%).² For this reason, extensive research has been conducted into obtaining a diagnosis of malignancy in patients with false negative results on pleural cytology, without the need to resort to invasive procedures such as biopsy by thoracoscopy. In this respect, measuring the concentrations of certain conventional tumor markers in pleural fluid is an attractive option, as this specimen is easy to obtain in clinical practice. However, there is no consensus on the most useful tumor markers and the most appropriate cutoff points to use.

Carcinoembryonic antigen (CEA) has been by far the most widely studied marker in PF, followed by others such as CYFRA 21-1 and carbohydrate antigen 15-3 (CA 15-3). Although evidence has shown that these markers can offer valuable information in some situations, neither the British³ nor the Spanish¹ guidelines recommend their routine use in PF.

This study reports the largest single-center series published to date on the potential utility of determining CEA and CA 15-3 in PF for identifying malignancy in the context of non-purulent exudate. This validates our previous experience⁴ and shows the added value of determining these tumor markers in addition to pleural cytology.

Materials and Methods

A retrospective review was conducted of all consecutive patients with pleural effusion referred by their treating physician to the Pleural Medicine Department of our hospital between August 2003 and August 2016 to undergo diagnostic thoracentesis with determination of CEA or CA 15-3 in the PF. The study was approved by the local ethics committee (CEIC-1713).

Diagnostic Variables and Criteria

Demographic data, results of the PF analysis, pathology studies and the final diagnosis of each patient were collected. Pleural effusion was defined as malignant if malignant cells were found in PF or in a pleural biopsy. Probably malignant pleural effusion (PMPE) was considered if 2 of the following conditions were met: (a) evidence of a primary tumor or extrapleural metastases, and (b) existence of a pleural exudate with negative cytological studies, not explained by causes other than tumor invasion of pleura, after performance of the clinical tests considered relevant by the treating physician and a sufficient follow-up period. Histological confirmation was always required for the diagnosis of pleural mesothelioma. Generally accepted criteria were used for diagnosing benign pleural effusion (BPE).⁵

Measuring Tumor Markers in Pleural Fluid

CEA and CA 15-3 in PF were measured in an Elecsys Roche electrochemiluminescence analyzer with a commercially available kit (Roche Diagnostics, Mannheim, Germany), according to the instructions of the manufacturer. Analyses were performed within hours of extraction of the PF specimen. In our laboratory, normal serum values are 0.2–5 ng/mL for CEA, and 1–30 IU/mL for CA 15-3.

Statistical Analysis

Data were expressed as number and percentage with their corresponding 95% confidence intervals (CI), or a median and 25%–75% quartiles. An analysis of the diagnostic efficacy curves (ROC) determined the yield of the tumor markers for identifying malignancy, seeking cutoff points with 100% specificity (i.e., no BPE above this threshold); these calculations were obtained excluding PMPE. Qualitative and quantitative variables between patients with MPE, PMPE, and BPE were compared using the Kruskal–Wallis and chi-squared tests, respectively. The frequency of elevated tumor markers among the different tumor types was compared using the chi-squared test with subsequent analysis of standardized residuals. Sensitivity and odds ratios were calculated using a 2×2 table. Calculations were performed using the SPSS statistical package, version 22.0.

Results

Study Population

During the study period, 2580 patients referred for CEA or CA 15-3 determinations in PF were identified. After exclusion of 191 empyemas (gross pus) and 814 individuals who met Light's criteria for transudate,⁶ the study population consisted of 1575 patients with non-purulent pleural exudates. Of these, 549 had cytologically demonstrated MPE, 284 had PMPE, and 742 had BPE (Table 1).

Diagnostic Efficacy of Tumor Markers in Pleural Fluid

Median concentrations of CEA and CA 15-3 in PE were significantly higher in MPE than in the other groups, and also significantly higher in PMPE than in BPE (Table 2).

ROC analysis of the MPE and BPE populations established pleural concentrations of CEA>45 ng/mL and CA 15-3>77 IU/mL as 100% specific cutoff points. In 41% (95% CI: 37–45) and 40% (95% CI: 36–44) of subjects with MPE, respectively, levels of these markers were above these limits. Moreover, 60% (95% CI: 56–64) of MPE patients had elevated levels of either of the 2 markers. Although elevated markers in PF was a definitive factor for confirming MPE (infinite positive probability ratios), their absence did not substantially modify the probability of cancer (negative probability ratios of 0.59 and 0.60 for CEA and CA 15-3, respectively, implying

Table 1
Causes of Pleural Exudate Among the Study Population.

Etiology	No. (%)
<i>Malignant pleural effusion</i>	549 (35)
Lung	214 ^a
Breast	96
Unknown origin	57
Ovarian	45
Gastrointestinal	43
Lymphoma	34
Mesothelioma	17
Miscellaneous	43
<i>Probably malignant pleural effusion</i>	284 (18)
Lung	125 ^b
Gastrointestinal	42
Breast	33
Unknown origin	16
Lymphoma	14
Ovarian	11
Miscellaneous	43
<i>Benign pleural effusion</i>	742 (47)
Pneumonia	177
Heart failure ^c	129
Tuberculosis	117
Pericardial diseases	66
Idiopathic	62
Post-heart, chest or abdominal surgery	55
Pulmonary embolism	29
Trauma	25
Connective tissue diseases	10
Miscellaneous	72

^a 158 adenocarcinomas, 19 squamous cell carcinomas, 19 small cell carcinomas, and 18 not specified were included.

^b 37 adenocarcinomas, 47 squamous cell carcinomas, 12 small cell carcinomas, and 30 not specified were included.

^c Pleural effusions due to heart failure, which met Light's criteria (mostly borderline) for exudate.

an absolute reduction in probability of only 15% approximately). Areas under the curve (AUC), as a discriminatory measure of efficacy, were 0.819 (95% CI: 0.793–0.845) for CEA and 0.822 (95% CI: 0.796–0.847) for CA 15-3.

Table 2
Demographic Characteristics and Pleural Concentrations of Tumor Markers Among the Study Groups.

Variable	MPE	PMPE	BPE	P
Age, years	70 (59–79)	70 (61–79)	69 (50–80)	.60
Sex, men, n (%)	274 (50)	163 (57)	483 (65) ^a	<.01
CEA, ng/mL	18.7 (1.8–180.9) ^a	4 (1.2–37.8) ^a	1.2 (0.7–1.8) ^a	<.01
CA 15-3, IU/mL	46.9 (16.4–160.5) ^a	16 (10.7–33.4) ^a	11.9 (7.8–17.5) ^a	<.01

Data are expressed as median (quartiles) or number (percentage), as applicable. BPE, benign pleural effusion; MPE, malignant pleural effusion; PMPE, probably malignant pleural effusion.

^a Statistically significant differences with respect to other groups.

Table 3
Sensitivity of Pleural CEA and CA 15-3 in Different Patient Groups with Malignant Effusion.

Marker	MPE	MPE with Negative PF Cytology ^a	PMPE	P ^b
CEA>45 ng/mL	226 of 549 41% (37–45)	14 of 46 30% (19–45)	67 of 283 24% (19–29)	.324
CA 15-3>77 IU/mL	202 of 506 40% (36–44)	8 of 42 19% (10–33)	32 of 253 13% (9–17)	.262
CEA>45 ng/mL or CA 15-3>77 IU/mL	317 of 527 60% (56–64)	18 of 44 41% (28–56)	92 of 261 35% (30–41)	.470

Data are expressed as absolute values and corresponding percentages, with 95% confidence intervals. MPE, malignant pleural effusion; PF, pleural fluid; PMPE, probably malignant pleural effusion.

^a Subgroup of patients with MPE proven by pleural biopsy, but with negative cytology studies.

^b For comparison between MPE with negative cytology and PMPE.

Tumor Markers in Malignant Effusions with Negative Cytological Studies

In the subgroup of patients positive for MPE by pleural biopsy but negative by PF cytology, CEA, CA 15-3, or a combination of either CEA or CA 15-3 (where a result was considered positive if either of the 2 markers was higher than the diagnostic cutoff) correctly predicted malignant PE in 30%, 19% and 41% of cases, respectively. These percentages were not significantly different in the population of patients with PMPE who, by definition also had negative results from PF cytology studies (24%, 13% and 25%, respectively) (Table 3).

Tumor Markers in Different Types of Primary Tumor

The yield of tumor markers in PF varied depending on the primary tumor (Table 4). The diagnostic sensitivity of CA 15-3 in ovarian tumors (79%), and of a combination of either CEA or CA 15-3 in gastrointestinal (83%), ovarian (81%), and lung (73%) adenocarcinomas was particularly notable. In contrast, the utility of both markers combined was practically zero in lymphomas and mesotheliomas (3% and 18%, respectively).

Diagnostic Sensitivity of the Combined Use of Cytology and Tumor Markers

The overall sensitivity of PF cytology studies was 60% (95% CI: 57–64), while the sensitivity of a combination of either CEA or CA 15-3 was 49% (95% CI: 46–52). When the results of both tests (positive cytology or markers higher than the diagnostic cutoff) were taken into consideration, sensitivity for identifying the malignant nature of an effusion rose to 74% (95% CI: 71–77).

Discussion

This study shows that the determination of CEA and CA 15-3 in PF can identify the tumor origin of over one third of MPE with negative cytology studies. These markers are more useful in the case of gastrointestinal, ovarian or lung adenocarcinomas that metas-

Table 4
Sensitivity of Pleural Fluid CEA and CA 15-3 in Malignant Effusions, by Primary Tumor Type.

Tumor Type	CEA>45 ng/mL (%)	CA 15-3>77 IU/mL (%)	CEA>45 ng/mL or CA 15-3>77 IU/mL (%)
Lung, adenocarcinoma	101 of 158 (64) ^a	66 of 145 (46)	113 of 154 (73) ^a
Lung, squamous cell	6 of 19 (32)	6 of 17 (35)	8 of 17 (47)
Lung, small cell	7 of 19 (37)	3 of 17 (18) ^b	8 of 18 (44)
Lung, not specified	10 of 18 (56)	6 of 17 (35)	12 of 18 (67)
Breast	34 of 96 (35)	50 of 96 (52) ^a	60 of 96 (63)
Unknown origin	29 of 57 (51)	19 of 53 (36)	37 of 56 (66)
Ovarian	1 of 45 (2) ^b	33 of 42 (79) ^a	34 of 42 (81) ^a
Gastrointestinal	34 of 43 (79) ^a	11 of 34 (32)	34 of 41 (83) ^a
Lymphoma	1 of 34 (3) ^b	0 of 33 (0) ^b	1 of 33 (3) ^b
Mesothelioma	0 of 17 (0) ^b	3 of 17 (18) ^b	3 of 17 (18) ^b
Miscellaneous	3 of 43 (7) ^b	5 of 34 (15) ^b	7 of 34 (21)

All $P < .01$

^a Percentages significantly higher than other tumors.

^b Percentages significantly lower than other tumors.

Table 5
Metaanalysis of Diagnostic Efficacy of Pleural CEA and CA 15-3 for Identifying Malignancy.

Study	Marker	No. of Studies/MPE/BPE	Sensitivity in %	Specificity in %	AUC
Gu et al. ⁷	CEA	15/1404/1543	46	97	0.77
Shi et al. ⁸	CEA	45/2834/3251	54	94	0.77
Nguyen et al. ⁹	CEA	49/NR/NR	55	96	0.81
	CA 15-3		51	98	0.78
Liang et al. ¹⁰	CA 15-3	11/819/966	51	96	0.73
	CEA+CA 15-3	3/208/366	66	98	0.88
Wu et al. ¹¹	CA 15-3	21/1472/1414	58	91	0.84

AUC, area under the curve; BPE, benign pleural effusion; MPE, malignant pleural effusion; NR, not reported.

tasize to the pleura, and negligible in the case of lymphomas and mesotheliomas.

CEA has been the most widely studied tumor marker in PF. Three metaanalyses have been published on the potential utility of these biomarkers in diagnostics, comprising 15, 45, and 49 studies each.^{7–9} The results, along with those from another 3 metaanalyses on the use of pleural CA 15-3,^{9–11} are summarized in Table 5. Recently, a Chinese study of 601 patients with MPE and 538 with BPE found pleural CEA to have 69% sensitivity and 82% specificity, with an AUC of 0.740.¹²

Taken together, the pooled sensitivities of these markers are very similar to those of PF cytology, but unlike the latter, they achieve absolute specificities with the (various) cutoff points proposed. This creates a margin of uncertainty in the interpretation of the CEA and CA 15-3 values that reduces their clinical applicability. Moreover, in previous studies, the BPE group has always included a considerable percentage of cardiac transudates and empyemas, effusions which, in practice, do not confound the differential diagnosis with MPE. These 2 limitations, the selection of tumor marker cutoffs that do not have absolute specificity and the inclusion of effusions with etiologies easily identifiable from a clinical point of view, have been resolved in this study. Nevertheless, the selection of 100% specific cutoffs reduces the sensitivity of any test; in this case, the percentage of patients with MPE who exceeded the established threshold for each individual tumor marker was around 40%. However, the combined use of either one or other of the 2 tumor markers raised sensitivity for detecting MPE up to 60%.

Finally, very few studies have provided data on the value of CEA and CA 15-3 in PMPE or MPE with negative cytology results.^{4,13,14} Indeed, this is the subset of patients in which measuring tumor markers in PE is of practical interest, since in patients with positive pleural cytologies, the diagnosis of malignancy is definitively established. In this respect, the behavior of the tumor markers was similar in MPE with negative pleural cytology and in PMPE: a combination of either CEA or CA 15-3 in PF led to 41% and 35% of these cases being classified as malignant, respectively.

The strengths of this study do not conceal its limitations. This was a retrospective evaluation performed in a single center, and the

results must be validated in independent populations in other centers. Nevertheless, we have been able to confirm the data that we obtained from a previous study conducted previously,⁴ and this, in a way, can be seen as a validation. Another potential limitation is the possibility that a “paramalignant” effusion (i.e., effusion not directly related with the tumor invading the pleura of a cancer patient) might have been erroneously included in the PMPE group. Although the clinical definition of PMPE was strict in order to avoid this occurrence, this patient group did not undergo a confirmatory pleuroscopy. In any case, similarities in the behavior of PF tumor markers in the MPE group with negative cytology and the PMPE group suggests that the classification of the latter was largely correct.

In conclusion, the determination of CEA and CA 15-3 in PF using 100% specific cutoffs contributes valuable clinical information by increasing our ability to identify MPE, notwithstanding the need for cytohistological confirmation in patients who may be candidates for receiving active oncological treatment.

Author Contributions

Study conception and design: J.M. Porcel. Data collection and analysis: C. Civit, A. Esquerda, A. Salud, S. Bielsa. Data interpretation: J.M. Porcel, S. Bielsa. Manuscript draft: J.M. Porcel. Critical review and approval of the final version of the manuscript: J.M. Porcel, C. Civit, A. Esquerda, A. Salud, S. Bielsa.

Conflict of Interest

The authors state that they have no conflict of interests.

References

- Villena V, Cases E, Fernández A, de Pablos A, Pérez-Rodríguez E, Porcel JM, et al. Normativa sobre el diagnóstico y tratamiento del derrame pleural. Actualización. Arch Bronconeumol. 2014;50:235–49.
- Porcel JM, Esquerda A, Vives M, Bielsa S. Etiología del derrame pleural: análisis de más de 3000 toracocentesis consecutivas. Arch Bronconeumol. 2014;50:161–5.

3. Hooper C, Lee YC, Maskell N, BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. *Thorax*. 2010;65 Suppl. 2:ii4–17.
4. Porcel JM, Vives M, Esquerda A, Salud A, Pérez B, Rodríguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. *Chest*. 2004;126:1757–63.
5. Porcel JM, Light RW. Pleural effusions. *Dis Mon*. 2013;59:29–57.
6. Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. *Ann Intern Med*. 1972;77:507–13.
7. Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. *J Clin Lab Anal*. 2007;21:398–405.
8. Shi HZ, Liang QL, Jiang J, Qin XJ, Yang HB. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. *Respirology*. 2008;13:518–27.
9. Nguyen AH, Miller EJ, Wichman CS, Berim IG, Agrawal DK. Diagnostic value of tumor antigens in malignant pleural effusion: a meta-analysis. *Transl Res*. 2015;166:432–9.
10. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. *Thorax*. 2008;63:35–41.
11. Wu Q, Li M, Zhang S, Chen L, Gu X, Xu F. Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: a meta-analysis. *Exp Ther Med*. 2015;9:232–8.
12. Li H, Huang L, Tang H, Zhong N, He J. Pleural fluid carcinoembryonic antigen as a biomarker for the discrimination of tumor-related pleural effusion. *Clin Respir J*. 2015, <http://dx.doi.org/10.1111/crj.12431> [Epub ahead of print].
13. Ferrer J, Villarino MA, Encabo G, Felip E, Bermejo B, Vilà S, et al. Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions. *Cancer*. 1999;86:1488–95.
14. Villena V, López-Encuentra A, Echave-Sustaeta J, Martín-Escribano P, Ortuño-de-Solo B, Estenoz-Alfaro J. Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4. *Lung Cancer*. 2003;40:289–94.